The U.S. Food and Drug Administration (FDA) approved this Monday the use of the Pfizer / BioNTech covid-19 booster vaccine for children between 12 and 15 years old, at consider that the benefits outweigh the risks.
“The benefits of a booster dose of Pfizer / BioNTech to provide continued protection against COVID-19 and the possible associated consequences of hospitalization and death outweigh the potential risks in individuals between the ages of 12 and 15,” the FDA said in a release.
In addition, the government entity also shortened the minimum time that must pass between the full schedule of the Pfizer vaccine and the booster dose, which will now be only five months, and approved the use of the booster dose in some children between 5 and 11 years with deficiencies in the immune system.
“With the current wave of the omicron variant, it is critical that we continue to take effective and life-saving preventative measures such as vaccination and booster doses, mask use and social distancing,” said Acting FDA Commissioner Janet Woodcock.
Those over 18 years old can already receive the booster dose of vaccines that have been available for weeks in the United States, while boys and girls between the ages of 5 and 11 began receiving their first injections last November.
The United States is experiencing a record of COVID-19 infections with the arrival of the omicron variant, with about 400 thousand a day in the last week.